<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23199">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01679613</url>
  </required_header>
  <id_info>
    <org_study_id>1199.161</org_study_id>
    <secondary_id>2012-001009-26</secondary_id>
    <nct_id>NCT01679613</nct_id>
  </id_info>
  <brief_title>Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers</brief_title>
  <official_title>Relative Bioavailability of Nintedanib Given Alone and in Combination With Ketoconazole at Steady State in Healthy Male Volunteers (an Open-label, Randomised, Two-way Cross-over Clinical Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the relative bioavailability of a
      single dose of nintedanib low or high dose with and without coadministration of ketoconazole
      at steady state
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</measure>
    <time_frame>up to 72 h postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma</measure>
    <time_frame>up to 72 h postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration</measure>
    <time_frame>up to 72 h postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1 Nintedanib (Reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose, oral with 240 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Nintedanib + Ketoconazole (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Nintedanib (Reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose, oral with 240 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Nintedanib + Ketoconazole (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>low or medium dose depending on pilot part</description>
    <arm_group_label>3 Nintedanib (Reference)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>low dose oral administration</description>
    <arm_group_label>1 Nintedanib (Reference)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>oral administration</description>
    <arm_group_label>2 Nintedanib + Ketoconazole (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>low dose oral administration</description>
    <arm_group_label>2 Nintedanib + Ketoconazole (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>low or medium dose depending on pilot part</description>
    <arm_group_label>4 Nintedanib + Ketoconazole (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>oral administration</description>
    <arm_group_label>4 Nintedanib + Ketoconazole (Test)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. healthy male subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1199.161.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 15, 2013</lastchanged_date>
  <firstreceived_date>September 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
